

Financial news for KIN dated on 2020-06-08: Kindred Biosciences Expects Restructuring To Be Completed In Q3 2020; To Record Charge Of About \$2.3M For Severance Payments, Health Care Benefits, Exclusive Of Stock Compensation

Financial news for KIN dated on 2020-06-08: Kindred Biosciences To Reduce Operating Expenses And Prioritize Investment In Highest Value, Late Stage Programs

Financial news for KIN dated on 2020-05-20: 52 Stocks Moving In Wednesday's Mid-Day Session

Financial news for KIN dated on 2020-05-20: Kindred Biosciences shares are trading higher the company announced a coronavirus vaccine manufacturing agreement with Vaxart.

Financial news for KIN dated on 2020-05-20: Vaxart Says Has Selected Its Lead COVID-19 Coronavirus Candidat

Financial news for KIN dated on 2020-05-20: Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement With Vaxart

Financial news for KIN dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for KIN dated on 2020-05-07: Kindred Biosciences Q1 EPS \$(0.580) Misses \$(0.430) Estimate, Sales \$603.000K Miss \$1.590M Estimate

Financial news for KIN dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Financial news for KIN dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for KIN dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for KIN dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for KIN dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for KIN dated on 2020-03-18: 130 Biggest Movers From Yesterday

Financial news for KIN dated on 2020-03-17: 94 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KIN dated on 2020-03-17: Stifel Maintains Buy on Kindred Biosciences, Lowers Price Target to \$13

Financial news for KIN dated on 2020-03-17: 10 Biggest Price Target Changes For Tuesday

Financial news for KIN dated on 2020-03-17: H.C. Wainwright Maintains Buy on Kindred Biosciences, Lowers Price Target to \$9

Financial news for KIN dated on 2020-03-16: Kindred Biosciences Q4 EPS \$(0.4) Misses \$(0.36) Estimate, Sales \$1.401M Beat \$1.3M Estimate

Financial news for KIN dated on 2020-03-16: Kindred Biosciences's Earnings Outlook

Financial news for KIN dated on 2020-03-16: Earnings Scheduled For March 16, 2020

Financial news for KIN dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for KIN dated on 2020-03-02: 140 Biggest Movers From Friday

Financial news for KIN dated on 2020-01-08: Kindred Biosciences Announces Half-Life Extension Technology For Canine Antibodies

Financial news for KIN dated on 2019-12-16: Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed

for the Treatment of Atopic Dermatitis in Dogs

Financial news for KIN dated on 2019-12-12: Kindred Biosciences Reports EC Approval Of Mirataz 20 mg/g Transdermal Ointment for Cats

Financial news for KIN dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for KIN dated on 2019-11-25: Kindred Biosciences Receives FDA Approval Of Zimeta For The Control Of Pyrexia In Horses

Financial news for KIN dated on 2019-11-12: Kindred Biosciences Q3 EPS \$(0.39) Misses \$(0.37) Estimate, Sales \$1.1M Miss \$1.66M Estimate

Financial news for KIN dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for KIN dated on 2019-10-10: Kindred Biosciences Announces Positive Opinion from CVMP in the European Union for Mirataz For Cats Experiencing Poor Appetite and Weight Loss

Financial news for KIN dated on 2019-09-16: 56 Biggest Movers From Friday

Financial news for KIN dated on 2019-09-10: Kindred Biosciences Awarded Contract By National Cancer Institute In Support Of PREVENT Cancer Program

Financial news for KIN dated on 2019-08-05: 82 Biggest Movers From Friday

Financial news for KIN dated on 2019-08-02: 40 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for KIN dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for KIN dated on 2019-07-29: 30 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for KIN dated on 2019-07-29: 35 Stocks Moving In Monday's Pre-Market Session

Financial news for KIN dated on 2019-07-29: Kindred Biosciences Announces Results From Pilot Field Effectiveness Study Of Its Interleukin-31 Monoclonal Antibody For The Treatment Of Atopic Dermatitis In Dogs

Financial news for KIN dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for KIN dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for KIN dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for KIN dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for KIN dated on 2019-07-17: 58 Biggest Movers From Yesterday

Financial news for KIN dated on 2019-07-16: 41 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KIN dated on 2019-07-16: 10 Biggest Price Target Changes For Tuesday

Financial news for KIN dated on 2019-07-16: B. Riley Downgrades Kindred Biosciences to Neutral, Lowers Price Target to \$8.5

Financial news for KIN dated on 2019-06-11: Barclays Initiates Coverage On Kindred Biosciences with Overweight Rating, Announces \$13 Price Target

Financial news for KIN dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for KIN dated on 2019-06-03: Companies Which Will Be Presenting At LD Micro's 9th Annual Micro Invitational Tues., Jun. 4, 2019

Financial news for KIN dated on 2019-05-23: Stifel Nicolaus Initiates Coverage On Kindred Biosciences, Inc. - Common Stock with Buy Rating, Announces \$14 Price Target

Financial news for KIN dated on 2019-05-09: Kindred Biosciences Q1 EPS \$(0.42) Misses \$(0.41) Estimate

Financial news for KIN dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for KIN dated on 2019-03-08: 64 Biggest Movers From Yesterday

Financial news for KIN dated on 2019-03-07: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for KIN dated on 2019-03-06: Kindred Biosciences shares are trading lower after the company announced worse-than-expected Q4 EPS results.

Financial news for KIN dated on 2019-03-06: Kindred Biosciences Q4 EPS \$(0.46) Misses \$(0.43) Estimate

Financial news for KIN dated on 2019-03-06: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

Financial news for KIN dated on 2019-01-24: The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial

Financial news for KIN dated on 2019-01-22: 52 Biggest Movers From Friday

Financial news for KIN dated on 2019-01-18: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for KIN dated on 2019-01-18: Kindred Biosciences shares are trading lower after the company announced a 4.215 million common stock offering at \$9.50 per share.

Financial news for KIN dated on 2019-01-18: Kindred Biosciences Prices 4.215M Share Common Stock Offering At \$9.50/Share

Financial news for KIN dated on 2019-01-18: The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Financial news for KIN dated on 2019-01-17: Kindred Biosciences Says it Expects 2018 Net Product Revenue of ~\$2M

Financial news for KIN dated on 2019-01-17: Kindred Biosciences Reports Proposed Common Stock Offering; No Size Disclosed

Financial news for KIN dated on 2019-01-14: Kindred Biosciences Reports Results From Pilot Field Effectiveness Study Of epoCat for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz(r) at Banfield Pet Hospital

Financial news for KIN dated on 2018-11-07: Kindred Biosciences Q3 EPS \$(0.39) Misses \$(0.37) Estimate, Sales \$640K

Financial news for KIN dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for KIN dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for KIN dated on 2018-11-01: 82 Biggest Movers From Yesterday

Financial news for KIN dated on 2018-10-31: 66 Stocks Moving In Wednesday's Mid-Day Session

Financial news for KIN dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for KIN dated on 2018-10-30: Kindred Biosciences shares are up 15.8% after the company reported 'positive' results from a study of IL-31 for atopic dermatitis in dogs and announced the issuance of a US patent.

Financial news for KIN dated on 2018-10-30: Kindred Biosciences Announces 'Positive' Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of US Patent

Financial news for KIN dated on 2018-08-09: Kindred Biosciences Q2 EPS \$(0.39),

Inline

Financial news for KIN dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for KIN dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for KIN dated on 2018-08-07: Benzinga's Top Upgrades, Downgrades For August 7, 2018

Financial news for KIN dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmmed's Antibiotic Faces FDA Panel

Financial news for KIN dated on 2018-08-07: Ladenburg Thalmann Downgrades Kindred Biosciences to Neutral

Financial news for KIN dated on 2018-08-02: Stocks Which Set New 52-Week High Yesterday, August 1st

Financial news for KIN dated on 2018-07-24: Cantor Fitzgerald Initiates Coverage On Kindred Biosciences with Overweight Rating, Announces \$20 Price Target

Financial news for KIN dated on 2018-07-23: Lake Street Initiates Coverage On Kindred Biosciences with Buy Rating, Announces \$30 Price Target

Financial news for KIN dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for KIN dated on 2018-07-20: Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

Financial news for KIN dated on 2018-07-18: Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

Financial news for KIN dated on 2018-07-10: 30 Biggest Movers From Yesterday

Financial news for KIN dated on 2018-07-09: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for KIN dated on 2018-07-09: Kindred Biosciences Announces Commercial Availability of Mirataz to Veterinarians in the United States

Financial news for KIN dated on 2018-06-20: Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program

Financial news for KIN dated on 2018-06-20: Kindred Biosciences Prices 4.6M Share Common Stock Offering At \$9.50/Share

Financial news for KIN dated on 2018-06-19: Kindred Biosciences Announces Common Stock Offering, No Size Disclosed

Financial news for KIN dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for KIN dated on 2018-06-14: Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi

Financial news for KIN dated on 2018-06-13: Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111

Financial news for KIN dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for KIN dated on 2018-05-08: Kindred Biosciences Q1 EPS \$(0.36), Inline

Financial news for KIN dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for KIN dated on 2018-05-07: Kindred Biosciences Announces Up to a \$50M Offering

Financial news for KIN dated on 2018-05-07: Kindred Biosciences Receives FDA Approval of Mirataz

Financial news for KIN dated on 2018-05-07: Kindred Biosciences Halted, News Pending

Financial news for KIN dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for KIN dated on 2018-04-24: UPDATE: Kindred Says FDA Has No Added Questions, Requests For Co. Related To Submission

Financial news for KIN dated on 2018-04-24: Kindred Biosciences Reports Received Response From FDA For Chemistry, Manufacturing, Controls Technical Section For Zimeta IV For Control Of Fever In Horses

Financial news for KIN dated on 2018-03-01: Kindred Biosciences Reports Q4 EPS \$(0.35) vs \$(0.31) Est.

Financial news for KIN dated on 2018-01-18: Kindred Biosciences S-3 Shows Registration For \$150M Mixed Securities Shelf Offering

Financial news for KIN dated on 2017-12-27: Benzinga's Top Upgrades, Downgrades For December 27, 2017

Financial news for KIN dated on 2017-12-21: KindredBio Announces Submission of European Medicines Agency Filing for Mirataz

Financial news for KIN dated on 2017-12-04: KindredBio Met Primary Endpoint For Zimeta Oral For Fever In Horses

Financial news for KIN dated on 2017-11-17: H.C. Wainwright Initiates Coverage On Kindred Biosciences with Buy Rating, Announces \$9.50 Price Target

Financial news for KIN dated on 2017-11-07: Kindred Biosciences Reports Q3 EPS \$(0.29) vs \$(0.33) Est.

Financial news for KIN dated on 2017-08-07: Kindred Biosciences Reports Q2 EPS \$(0.29) vs \$(0.32) Est.

Financial news for KIN dated on 2017-07-12: Filing From Kindred Biosciences Shows 3M Share Common Stock Offering Priced At \$7.85/Share

Financial news for KIN dated on 2017-07-12: 10 Biggest Mid-Day Losers For Wednesday

Financial news for KIN dated on 2017-07-12: KindredBio Prices 3M Share Offering At \$7.50/Share

Financial news for KIN dated on 2017-07-12: Kindred Bioscience Shares Down 3.8% In Pre-Market Following Common Stock Offering Reported Tuesday After-Hours, No Amount Disclosed

Financial news for KIN dated on 2017-07-12: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for KIN dated on 2017-07-11: Kindred Biosciences Reports Offering Of Common Stock, No Amount Disclosed

Financial news for KIN dated on 2017-06-26: Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant For \$3.75M and Execution of Commercial Manufacturing Agreement for Zimeta

Financial news for KIN dated on 2017-06-16: Benzinga's Top Upgrades, Downgrades For June 16, 2017

Financial news for KIN dated on 2017-06-16: Aegis Capital Initiates Coverage On Kindred Biosciences with Buy Rating, Announces \$10.50 Price Target

Financial news for KIN dated on 2017-05-24: Benzinga's Top Upgrades, Downgrades For May 24, 2017

Financial news for KIN dated on 2017-05-24: FBR Capital Initiates Coverage On Kindred Biosciences with Outperform Rating, Announces \$10.00 Price Target

Financial news for KIN dated on 2017-05-16: Kindred Biosciences 10%+ Owner Park West Asset Management Buys 155,076 Shares @ Avg Price: \$6.82 -Form4

Financial news for KIN dated on 2017-05-03: Kindred Biosciences Reports Q1 EPS \$(0.30) vs \$(0.34) Est.

Financial news for KIN dated on 2017-05-01: Kindred Biosciences Reports Initiation of Enrollment for Pivotal Effectiveness of Zimeta Oral for Control of Fever in Horses

Financial news for KIN dated on 2017-03-01: Kindred Biosciences Reports Q4 EPS \$(0.29) vs \$(0.36) Est.

Financial news for KIN dated on 2017-02-06: Kindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz New Animal Drug Application

Financial news for KIN dated on 2016-11-18: KeyBanc Downgrades Kindred Biosciences to Sector Weight

Financial news for KIN dated on 2016-11-07: Kindred Biosciences Reports Q3 EPS \$(0.29) vs. Est. \$(0.33)

Financial news for KIN dated on 2016-11-01: Kindred Biosciences Is 'Setting The Pace In Animal Health Biologics'

Financial news for KIN dated on 2016-11-01: Benzinga's Top Initiations

Financial news for KIN dated on 2016-11-01: Ladenburg Thalmann Initiates Coverage On Kindred Biosciences, Inc. - Common Stock at Buy, Announces \$7.50

Financial news for KIN dated on 2016-10-04: UPDATE: Kindred Expects The Approval of Zimeta In 1H17 If FDA Review Process Is Rapid

Financial news for KIN dated on 2016-10-04: Kindred Biosciences Receives Approval of Effectiveness Technical Section From FDA For Zimeta New Animal Drug application

Financial news for KIN dated on 2016-09-30: Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Mirataz to FDA and Launches KindredBio Equine Website

Financial news for KIN dated on 2016-08-22: Kindred Biosciences Submits Drug Application Technical Section for Effectiveness for Mirataz to FDA

Financial news for KIN dated on 2016-08-08: Kindred Biosciences Reports Q2 EPS \$(0.25) vs \$(0.32) Est.

Financial news for KIN dated on 2016-06-14: Kindred Biosciences Announces Initiation of Pilot Field Study of Atopic Dermatitis and Other Updates

Financial news for KIN dated on 2016-05-05: Kindred Biosciences Reports Q1 EPS \$(0.31) Vs Est \$(0.32)

Financial news for KIN dated on 2016-03-17: Director Mario Buys 30,000 Shares of Kindred Biosciences @\$3.55/Share -Form 4

Financial news for KIN dated on 2016-03-15: Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

Financial news for KIN dated on 2016-03-02: Kindred Biosciences Reports Q4 EPS \$(0.32) vs \$(0.44) Est.

Financial news for KIN dated on 2016-02-11: Kindred Biosciences Submits Zimeta New Animal Drug Application Technical Section for Effectiveness to FDA

Financial news for KIN dated on 2016-01-26: UPDATE: Kindred Biosciences KIND-010 Showed 3.25% Weight Gain vs. Placebo Loss Of 1.65% With Statistical Significant Results (P=0.0042)

Financial news for KIN dated on 2016-01-26: Kindred Biosciences Offers Results of Pilot Field Study of KIND-010 for Mgmt of Weight in Cats

Financial news for KIN dated on 2016-01-11: Kindred Biosciences To Reduce Workforce By 31%

Financial news for KIN dated on 2016-01-07: Kindred Biosciences Says Will Offer corporate Update on Mon., Jan. 11

Financial news for KIN dated on 2015-12-17: Kindred Biosciences Reports Submission of KIND-012 NADA Technical Section for Chemistry, Manufacturing, Controls to FDA

Financial news for KIN dated on 2015-11-17: Benzinga's Top Downgrades

Financial news for KIN dated on 2015-11-17: BMO Capital Downgrades Kindred Biosciences to Market Perform, Lowers PT to \$5.00

Financial news for KIN dated on 2015-11-16: Kindred Biosciences Shares to Resume Trade at 9 a.m. EST

Financial news for KIN dated on 2015-11-16: Kindred Reports Positive Results from Pivotal Study of KIND-012 for Pyrexia: Study Met Primary Endpoint, SentiKind Study

Misses Primary Endpoint

Financial news for KIN dated on 2015-11-16: Kindred Biosciences Shares Halted News Pending

Financial news for KIN dated on 2015-11-09: Kindred Biosciences Reports Q3 EPS \$(0.36) vs \$(0.44) Est.

Financial news for KIN dated on 2015-08-10: Kindred Biosciences Reports Q2 Loss of \$0.35/Share vs Loss of \$0.44/Share Est.

Financial news for KIN dated on 2015-03-16: UPDATE: Kindred Biosciences Pilot Field Study of KIND-012 for the Control of Fever in Horses Met Primary Endpoint

Financial news for KIN dated on 2015-03-16: Kindred Biosciences Announces Results of Pilot Field Study of KIND-012 for Control of Fever in Horses: Shows Primary Endpoint Met

Financial news for KIN dated on 2015-03-12: KIndred Biosciences Reports Q4 EPS \$(0.34) vs. Est. \$(0.43)

Financial news for KIN dated on 2015-03-12: Earnings Scheduled For March 12, 2015

Financial news for KIN dated on 2015-01-16: S-3 from Kindred Biosciences Shows Registration for \$150M Mixed Securities Shelf

Financial news for KIN dated on 2014-12-04: Mid-Day Losers From December 4: Kindred Biosciences, Barnes & Noble, Aeropostale

Financial news for KIN dated on 2014-12-04: Stocks Hitting 52-Week Lows

Financial news for KIN dated on 2014-12-04: Morning Market Losers

Financial news for KIN dated on 2014-12-04: Benzinga's Top Downgrades

Financial news for KIN dated on 2014-12-04: Leerink Swann Downgrades Kindred Biosciences To Market Perform

Financial news for KIN dated on 2014-12-04: Benzinga's Top #PreMarket Losers

Financial news for KIN dated on 2014-12-04: Leerink Swann Downgrades Kindred Biosciences to Market Perform, Lowers PT to \$6.00

Financial news for KIN dated on 2014-12-03: Shares of Kindred Biosciences to Resume Trade at 4:30 p.m. EDT

Financial news for KIN dated on 2014-12-03: KindredBio Announces Will Stop Atokin Study

Financial news for KIN dated on 2014-12-03: Shares of Kindred Bioscience Halted News Pending

Financial news for KIN dated on 2014-08-21: Morning Market Losers

Financial news for KIN dated on 2014-08-21: Kindred Bio Goes To The Dogs; Lead Drug Candidate Washes Out

Financial news for KIN dated on 2014-08-21: Benzinga's Top #PreMarket Losers

Financial news for KIN dated on 2014-08-20: Kindred Biosciences Shares to Resume Trade at 4:30p.m. EDT

Financial news for KIN dated on 2014-08-20: UPDATE: Kindred Biosciences Reports Results from PIVOTAL Study of CereKin in Dogs, Primary Endpoint Was Not Met

Financial news for KIN dated on 2014-08-20: Kindred Biosciences Reports Results from PIVOTAL Study of CereKin in Dogs, Primary Endpoint Was Not Met

Financial news for KIN dated on 2014-08-20: Kindred Biosciences Halted News Pending

Financial news for KIN dated on 2014-08-13: Kindred Biosciences Reports Q2 EPS of \$(0.42) vs \$(0.35) Est

Financial news for KIN dated on 2014-05-23: Morning Market Movers Friday, May 23, 2014

Financial news for KIN dated on 2014-05-12: Kindred Biosciences Reports Q1 EPS of \$(0.38) vs \$(0.19) Est

Financial news for KIN dated on 2014-04-14: Leerink Swann Initiates Coverage on Kindred Biosciences at Outperform, Announces \$32.00 PT

Financial news for KIN dated on 2014-04-08: Kindred Bio Closes Public Offering, Estimates Net Proceeds of \$58.1M

Financial news for KIN dated on 2014-04-03: Morning Market Losers

Financial news for KIN dated on 2014-04-03: Kindred Bio Prices 3M Shares at \$18/Share

Financial news for KIN dated on 2014-03-31: UPDATE: Kindred Bio Announces Launch of \$50M Public Offering

Financial news for KIN dated on 2014-03-31: Kindred Bio Announces \$50M Offering of Common Stock

Financial news for KIN dated on 2014-03-28: Kindred Bio Announces Initiation of Pivotal Clinical Study for SentiKin in Dogs

Financial news for KIN dated on 2014-03-24: Morning Market Losers

Financial news for KIN dated on 2014-03-07: Roth Capital Downgrades Kindred Biosciences to Neutral, Raises PT to \$25.00

Financial news for KIN dated on 2014-02-25: BMO Capital Upgrades Kindred Biosciences to Outperform, Raises Pt to \$30.00

Financial news for KIN dated on 2014-02-13: 13F Filing from Seth Klarman's Baupost Group Shows New Stake in Kindred Biosciences, Liquidated Stake in Oracle

Financial news for KIN dated on 2014-02-04: Roth Capital Initiates Coverage on Kindred Biosciences at Buy, Announces \$20.00 PT

Financial news for KIN dated on 2014-01-22: BMO Capital Downgrades Kindred Biosciences to Market Perform

Financial news for KIN dated on 2014-01-09: 13G Filing from Seth Klarman's Baupost Group Shows 17.93% Stake in Kindred Biosciences

Financial news for KIN dated on 2013-12-13: Director Nodelman Buys 400,000 Shares of Kindred Biosciences -Form 4